Following a bustling week in the primary market, the spotlight now turns to a fresh set of public offerings. Four mainboard IPOs are scheduled to hit the market in the coming week, with two of them—Wakefit Innovations and Corona Remedies—opening for subscription on Monday, December 8, 2025.
IPO Grey Market Sentiment and Pricing Details
The grey market, an unofficial platform for trading IPO shares before listing, shows contrasting sentiment for the two issues. Corona Remedies is witnessing strong demand, with its shares commanding a substantial grey market premium (GMP) of ₹365. This indicates a potential listing price of around ₹1,427, which would be a significant 34.37% premium over its upper issue price of ₹1,062.
In comparison, Wakefit Innovations is seeing moderate enthusiasm. Its shares are trading at a GMP of ₹36, suggesting a likely listing price of approximately ₹231. This translates to an 18.5% premium over its upper price band of ₹195 per share.
The subscription window for both IPOs will remain open from December 8 to December 10, 2025. The allotment for both issues is expected to be finalized on December 11, 2025, with tentative listing on both BSE and NSE scheduled for December 15, 2025.
Wakefit Innovations IPO: From Mattresses to Full Home Solutions
Wakefit Innovations Ltd, the well-known home and furnishings brand, aims to raise ₹1,288.89 crore through its initial public offering. The issue comprises a fresh equity issuance worth ₹377.18 crore and an offer for sale (OFS) component of ₹911.71 crore by existing shareholders.
The company has set a price band of ₹185 to ₹195 per share. For retail investors, the lot size is 76 shares, requiring a minimum investment of ₹14,820 at the upper end of the price band.
Proceeds from the fresh issue will be utilized for several growth initiatives:
- Opening 117 new company-owned, company-operated (COCO) stores.
- Acquiring new equipment and machinery.
- Enhancing marketing and advertising efforts.
- Covering rental and licence fees for existing COCO stores.
- General corporate purposes.
Founded as a direct-to-consumer mattress seller, Wakefit has successfully expanded into furniture and home furnishings, transforming into a comprehensive home solutions brand. The company claims to be the fastest homegrown organised player to cross the ₹1,000 crore total income milestone in under a decade. Its competitors include established names like Lifestyle International, Godrej & Boyce, Sheela Foam, and IKEA India.
Axis Capital Ltd. is the book-running lead manager for the Wakefit IPO, while MUFG Intime India Pvt. Ltd. is the registrar.
Corona Remedies IPO: A Pure Offer for Sale
The Corona Remedies IPO is a ₹655.37 crore book-built issue. Unlike the Wakefit offering, this is entirely an offer for sale (OFS) of 0.62 crore shares. This means the company will not receive any proceeds from the IPO; all funds will go to the selling shareholders.
The promoters and investors participating in the OFS include Kirtikumar Laxmidas Mehta, Minaxi Kirtikumar Mehta, Dipabahen Niravkumar Mehta, Brinda Ankur Mehta, Sepia Investments Limited, Anchor Partners, and Sage Investment Trust.
The IPO price band is fixed at ₹1008 to ₹1062 per share. The lot size for retail investors is 14 shares, translating to a minimum application amount of ₹14,868.
Based in Gujarat, Corona Remedies is a pharmaceutical company with a portfolio focused on key therapeutic areas such as women’s healthcare, cardio-diabetes, pain management, and urology. It operates two manufacturing facilities located in Gujarat and Himachal Pradesh.
JM Financial Ltd. is the book-running lead manager for this issue, and Bigshare Services Pvt. Ltd. is the registrar.
What This Means for Investors
The launch of these IPOs marks another active phase for the primary market, offering investors exposure to two distinct sectors—consumer retail and pharmaceuticals. The strong grey market premium for Corona Remedies reflects high investor interest, potentially driven by its niche focus and established manufacturing base. Wakefit's offering represents the growth story of a digital-native brand scaling into physical retail.
Investors should carefully review the prospectuses, company fundamentals, and risk factors before applying. The upcoming week will also see the opening of two other mainboard IPOs—Park Medi World and Nephrocare Health Services—further diversifying options for market participants.
